Ran Geng is a venture investor at Matrix Partners China focused on biotech investments. She invests in first-in-class or best-in-class therapeutics that has the potential of transforming a therapeutic area. She led or is involved in the investment of Nikang Therapeutics, InventisBio, Rootpath, Chameleon Bio, Peijia Medical (HK.9996), Ambrx, etc, Her investments have led to 3 positive clinical POCs. Ran was a consultant at ZS Associates, working for the headquarters of Roche/Genentech, Gilead, and Novartis on M&A, go/no-go criteria, and clinical development strategies. Her work led to Roche’s $4.3B acquisition of SPARK Therapeutics, and Gilead’s $11.9B acquisition of Kite Pharma.
Ran graduated from University of Pennsylvania and Wharton Business School’s Roy Vagelos Life Science Management Program with B.S. in Computational Biology and B.S.E in Operations Management. She was also a certified Emergency Medical Technician.